1)日本循環器学会,日本心不全学会,日本心臓病学会,他:日本循環器学会/日本心不全学会合同ガイドライン 心筋症診療ガイドライン(2018年改訂版),2021(https://www.j-circ.or.jp/cms/wp-content/uploads/2018/08/JCS2018_tsutsui_kitaoka.pdf)(最終アクセス:2021年11月26日)
2)Spirito P, Bellone P, Harris KM, et al:Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1778-1785,2000
3)Elliott PM, Anastasakis A, Borger MA, et al:2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733-2779,2014
4)Goto D, Kinugawa S, Hamaguchi S, et al:Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy: report from the registry data in Japan. J Cardiol 61:65-70,2013
5)Maron BJ, Gottdiener JS, Epstein SE:Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 48:418-428,1981
6)Nagueh SF, Smiseth OA, Appleton CP, et al:Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29:277-314,2016
7)Ibrahim M, Rao C, Ashrafian H, et al:Modern management of systolic anterior motion of the mitral valve. Eur J Cardiothorac Surg 41:1260-1270,2012
8)To AC, Dhillon A, Desai MY:Cardiac magnetic resonance in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 4:1123-1137,2011